دورية أكاديمية
Systemic Anticancer Therapy and Thromboembolic Outcomes in Hospitalized Patients With Cancer and COVID-19
| العنوان: | Systemic Anticancer Therapy and Thromboembolic Outcomes in Hospitalized Patients With Cancer and COVID-19 |
|---|---|
| المؤلفون: | Gulati, Shuchi, Hsu, Chih-Yuan, Shah, Surbhi, Shah, Pankil K., Zon, Rebecca, Alsamarai, Susan, Awosika, Joy, El-Bakouny, Ziad, Bashir, Babar, Beeghly, Alicia, Berg, Stephanie, de-la-Rosa-Martinez, Daniel, Doroshow, Deborah B., Egan, Pamela C., Fein, Joshua, Flora, Daniel B., Friese, Christopher R., Fromowitz, Ariel, Griffiths, Elizabeth A., Hwang, Clara, Jani, Chinmay, Joshi, Monika, Khan, Hina, Klein, Elizabeth J., Heater, Natalie Knox, Koshkin, Vadim S., Kwon, Daniel H., Labaki, Chris, Latif, Tahir, McKay, Rana R., Nagaraj, Gayathri, Nakasone, Elizabeth S., Nonato, Taylor, Polimera, Hyma V., Puc, Matthew, Razavi, Pedram, Ruiz-Garcia, Erika, Saliby, Renee Maria, Shastri, Aditi, Singh, Sunny R.K., Tagalakis, Vicky, Vilar-Compte, Diana, Weissmann, Lisa B., Wilkins, Cy R., Wise-Draper, Trisha M., Wotman, Michael T., Yoon, James J., Mishra, Sanjay, Grivas, Petros, Shyr, Yu, Warner, Jeremy L., Connors, Jean M., Shah, Dimpy P., Rosovsky, Rachel P. |
| المصدر: | Kimmel Cancer Center Faculty Papers |
| بيانات النشر: | Jefferson Digital Commons |
| سنة النشر: | 2023 |
| المجموعة: | Jefferson Digital Commons (Thomas Jefferson University, Philadelphia) |
| مصطلحات موضوعية: | Medicine and Health Sciences, Oncology, Virus Diseases |
| الوصف: | IMPORTANCE: Systematic data on the association between anticancer therapies and thromboembolic events (TEEs) in patients with COVID-19 are lacking. OBJECTIVE: To assess the association between anticancer therapy exposure within 3 months prior to COVID-19 and TEEs following COVID-19 diagnosis in patients with cancer. DESIGN, SETTING, AND PARTICIPANTS: This registry-based retrospective cohort study included patients who were hospitalized and had active cancer and laboratory-confirmed SARS-CoV-2 infection. Data were accrued from March 2020 to December 2021 and analyzed from December 2021 to October 2022. EXPOSURE: Treatments of interest (TOIs) (endocrine therapy, vascular endothelial growth factor inhibitors/tyrosine kinase inhibitors [VEGFis/TKIs], immunomodulators [IMiDs], immune checkpoint inhibitors [ICIs], chemotherapy) vs reference (no systemic therapy) in 3 months prior to COVID-19. MAIN OUTCOMES AND MEASURES: Main outcomes were (1) venous thromboembolism (VTE) and (2) arterial thromboembolism (ATE). Secondary outcome was severity of COVID-19 (rates of intensive care unit admission, mechanical ventilation, 30-day all-cause mortality following TEEs in TOI vs reference group) at 30-day follow-up. RESULTS: Of 4988 hospitalized patients with cancer (median [IQR] age, 69 [59-78] years; 2608 [52%] male), 1869 had received 1 or more TOIs. Incidence of VTE was higher in all TOI groups: endocrine therapy, 7%; VEGFis/TKIs, 10%; IMiDs, 8%; ICIs, 12%; and chemotherapy, 10%, compared with patients not receiving systemic therapies (6%). In multivariable log-binomial regression analyses, relative risk of VTE (adjusted risk ratio [aRR], 1.33; 95% CI, 1.04-1.69) but not ATE (aRR, 0.81; 95% CI, 0.56-1.16) was significantly higher in those exposed to all TOIs pooled together vs those with no exposure. Among individual drugs, ICIs were significantly associated with VTE (aRR, 1.45; 95% CI, 1.01-2.07). Also noted were significant associations between VTE and active and progressing cancer (aRR, 1.43; 95% CI, 1.01-2.03), history of ... |
| نوع الوثيقة: | article in journal/newspaper |
| وصف الملف: | application/pdf |
| اللغة: | English |
| العلاقة: | https://jdc.jefferson.edu/kimmelccfp/109Test; https://jdc.jefferson.edu/context/kimmelccfp/article/1109/viewcontent/jamaoncology_gulati_2023_oi_230039_1697125882.54833.pdfTest; https://jdc.jefferson.edu/context/kimmelccfp/article/1109/filename/0/type/additional/viewcontent/Supplemental_Material_1.pdfTest; https://jdc.jefferson.edu/context/kimmelccfp/article/1109/filename/1/type/additional/viewcontent/Supplemental_Material_2.pdfTest; https://jdc.jefferson.edu/context/kimmelccfp/article/1109/filename/2/type/additional/viewcontent/Supplemental_Material_3.pdfTest |
| الإتاحة: | https://jdc.jefferson.edu/kimmelccfp/109Test https://jdc.jefferson.edu/context/kimmelccfp/article/1109/viewcontent/jamaoncology_gulati_2023_oi_230039_1697125882.54833.pdfTest https://jdc.jefferson.edu/context/kimmelccfp/article/1109/filename/0/type/additional/viewcontent/Supplemental_Material_1.pdfTest https://jdc.jefferson.edu/context/kimmelccfp/article/1109/filename/1/type/additional/viewcontent/Supplemental_Material_2.pdfTest https://jdc.jefferson.edu/context/kimmelccfp/article/1109/filename/2/type/additional/viewcontent/Supplemental_Material_3.pdfTest |
| حقوق: | http://creativecommons.org/licenses/by/4.0Test/ |
| رقم الانضمام: | edsbas.647930EF |
| قاعدة البيانات: | BASE |
| الوصف غير متاح. |